Cardarine 10 mg 50 tablets
$100.00
Chemical Name: 2-{2-methyl-4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid
Molecular Weight: 453.5
Formula: C21 H18 F3 NO3 S2
Melting Point: 139-145C
Manufacturer: Various
Effective Dose: (Men) 10-20 mgs/day – (Women) 5-10 mgs/day
Active Life: 12-24 hours
Detection Time: 5 days
Anabolic/Androgenic Ratio (Range): N/A
GW-501516, better known as Cardarine, is a unique medication officially classified as a PPAR receptor agonist (PPAR-RA). Research for this medication began in 1992 in a conjoined effort between GlaxoSmithKline (GSK) and Ligand Pharmaceuticals. Research into this product was set forth in an effort to provide treatment for various cardiovascular diseases, as well as diabetes, obesity and other conditions. It was soon discovered that the PPAR-RA was highly effective at enhancing endurance, but it was also shown to carry a high potential cost. It was discovered that Cardarine increased the chances of cancer significantly, and as a result, GSK dropped all further research. However, the studies that produced cancerous results used doses of Cardarine that were 500 to even 1000 times the amount that a human being would take. If cancer is a risk with standard dosing is unknown.
